Tag: GlobeNewswire

Lyon (France), October 07, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that, following a further benefit-risk assessment of IXCHIQ^® for travelers by the United Kingdom’s (UK) Commission on Human Medicines (CHM), the UK marketing authorization for IXCHIQ^® has been revoked by the Medicines and Healthcare products Regulatory Agency (MHRA). The decision was based on a review of previous safety data and was not associated with any newly identified safety signal. It does not affect the product licenses for IXCHIQ^® in the EU, Canada, Brazil, or other territories where IXCHIQ^® is currently marketed.

IXCHIQ^® was launched in the UK in mid-2025. Due to low sales amongst travelers, Valneva has not actively distributed IXCHIQ^® in the UK for several months. As no product currently remains on the UK market, Valneva expects no expense related to product recall and only minimal impact on its overall sales revenue going forward.

Valneva considers the benefit-risk profile of IXCHIQ^® favorable when used in accordance with the approved indication, contraindications, warnings and precautions. This is further supported by the emerging post-marketing evidence, including the ongoing pilot vaccination strategy (PVS)¹ in Brazil, where more than 61,000 people aged 18-59 years have been vaccinated to date with no new safety concerns identified. Similar safety reviews were concluded recently by the European Medicines Agency (EMA) and by Health Canada, which maintained the marketing authorizations for IXCHIQ^®, with updated product information. To date, approximately 187,000 doses of IXCHIQ^® have been administered globally.

While the Company disagrees with CHM’s and MHRA’s conclusion, Valneva has decided not to appeal the decision, given its immaterial financial and commercial impact, and in line with the Company’s strategic focus on expanding access to IXCHIQ^® in endemic territories, where the risk of chikungunya virus infection is highest.

About Chikungunya
Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes which causes fever, severe joint and muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years². In 2004, the disease began to spread quickly, causing large-scale outbreaks around the world. Since the re-emergence of the virus, CHIKV has been identified in over 110 countries in Asia, Africa, Europe and the Americas3. Between 2013 and 2023, more than 3.7 million cases were reported in the Americas³ and the economic impact is considered to be significant. The medical and economic burden is expected to grow with climate change as the mosquito vectors that transmit the disease continue to spread geographically. As such, the World Health Organization (WHO) has highlighted chikungunya as a major public health problem⁴.

About Valneva SE
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.

Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 laetitia.bachelotfontaine@valneva.com

Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in France. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements with respect to: the impact of the UK MHRA revocation of the UK marketing authorization for IXCHIQ® on Valneva’s business, financial condition, and results of operations; Valneva’s expectations regarding the financial and commercial impact of the MHRA’s decision and its decision not to appeal; the continued validity and status of IXCHIQ®’s product licenses and marketing authorizations in the EU, Canada, Brazil, and other territories where IXCHIQ® is currently marketed; and Valneva’s assessment of the benefit-risk profile of IXCHIQ® and the outcome of related or future regulatory reviews, including by other health authorities. These forward-looking statements are based on Valneva’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Valneva’s business, strategy, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: Valneva’s success in the commercialization of its commercial products; uncertainties and delays involved in the development and manufacture of vaccines; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies and uncertainty related to such policies; the conflicts in Ukraine, Iran and the Middle East; fluctuations in inflation and uncertain credit and financial markets and their resulting impacts on Valneva’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; Valneva’s ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; the impact of the global and European credit crisis; the ability to obtain or maintain patent or other proprietary intellectual property protection and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled “Risk Factors” in Valneva’s Annual Report on Form 20-F for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (“SEC”) and the Autorité des marchés financiers (“AMF”) on March 18, 2026, and in other filings made with the SEC and AMF from time to time. Valneva is providing this information as of the date of this press release and expressly disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

---

1 Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ^®
2 Reemergence of Chikungunya Virus
³ Vaccine and Therapeutic Options To Control Chikungunya Virus
⁴ Geographical expansion of cases of dengue and chikungunya beyond the historical areas of transmission in the Region of the Americas (who.int)

Attachment

• 2026_10_07_IXCHIQ_Update_UK_PR_EN

RESTON, Va., Oct. 07, 2026 (GLOBE NEWSWIRE) — Stride Inc. (NYSE: LRN) announced today its plans to discuss its first quarter fiscal year 2027 financial results during a conference call scheduled for Tuesday, October 20, 2026 at 5:00 p.m. (ET).

A live webcast of the call will be available at investors.stridelearning.com/events-and-presentations. To participate in the live call, investors and analysts should dial (833) 461-5787 (domestic) or +1 (585) 542-9983 (international) and provide the conference ID number 305 592 627. Please access the website at least 15 minutes prior to the start of the call.

A replay of the call will be posted at investors.stridelearning.com/events-and-presentations as soon as it is available.

About Stride Inc.

Stride Inc. (NYSE: LRN) is redefining lifelong learning with innovative, high-quality education solutions. Serving learners in primary, secondary, and postsecondary settings, Stride provides a wide range of services including K-12 education, career learning, professional skills training, and talent development. Stride reaches learners in all 50 states and over 100 countries. Learn more at stridelearning.com.

Investor Contact
Investor Relations
Stride, Inc.
ir@k12.com

SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders

Proposed acquisition expected to accelerate development of CERo’s lead product candidate, CER-1236, for hematologic malignancies

NORTH PALM BEACH, Fla., Oct. 07, 2026 (GLOBE NEWSWIRE) — SRX Global Inc. (NYSE American: SRXH) (the “Company” or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has entered into definitive purchase agreement under which CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo Holdings” and, together with CERo Therapeutics, “CERo”), an innovative cellular immunotherapy company advancing the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, will become a wholly owned subsidiary of SRX Global.

The pending transaction is expected to accelerate the advancement of CERo’s clinical programs. The combination of Cero and the CERO 1236 SPV is expected to benefit from enhanced access to capital. The transaction combines SRX Global’s public company infrastructure with CERo’s innovative oncology platform.

Chief Executive Officer of SRX Global Inc., Kent Cunningham stated, “This proposed acquisition reflects our strategy of investing in high-conviction operating companies with meaningful long-term value creation potential. CERo’s differentiated approach to engineered T cell therapeutics, and the clinical progress the team has made with CER-1236, make it a compelling addition to our platform. We expect this transaction to give CERo enhanced access to capital and broader operational resources to support continued advancement of CER-1236 and its broader R&D efforts, while providing SRX shareholders exposure to an innovative oncology asset.”

CERo Chief Executive Officer, Chris Ehrlich added, “This proposed transaction represents an important development for CERo and our mission to develop potentially life-prolonging therapies for patients experiencing rare and difficult-to-treat cancers. By becoming part of SRX, we expect CERo Therapeutics to benefit from broader operational resources that can support the continued advancement of CER-1236 and our broader R&D efforts. We believe the proposed transaction provides a stronger platform from which to execute our clinical development strategy and create long-term value for patients and shareholders.”

Under the terms of the proposed transaction, Andrew (“Al”) Kucharchuk, currently CERo Chief Financial Officer, is expected to serve as President of and primary executive of CERo Therapeutics following the closing of the proposed transaction. Chris Ehrlich and current CERo director Brian Atwood are each expected to serve on the CERo Therapeutics Board of Directors and as Special Advisors to the President. This leadership structure is intended to provide continuity for CERo Therapeutics operations.

To date, CERo has reported treating six patients in the ongoing Phase 1 CERTAIN-T trial. In the most recent cohort of three patients, CER-1236 was administered at an increased dose level, with no dose-limiting toxicities (“DLTs”) observed during the DLT assessment period. As previously reported, CERo has also observed expansion of infused CER-1236 cells following administration, and CERo continues to evaluate the pharmacokinetic and pharmacodynamic profile of CER-1236 as the study advances through dose escalation. These clinical results are preliminary and are not sufficient to establish the safety or efficacy of CER-1236.

CERo has initiated the third planned cohort of the CERTAIN-T study, which is expected to evaluate the planned one billion cells/patient protocol and is currently screening patients for enrollment. The cohort is also expected to include patients with myelodysplastic syndromes (“MDS”) and myelofibrosis (“MF”), reflecting CERo’s strategy to further evaluate CER-1236 in additional myeloid disease settings.

About the CERTAIN-T Trial
The first-in-human, multicenter, open-label Phase 1/1b CERTAIN-T study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of CER-1236 in patients with hematologic malignancies. The study initially enrolled patients with acute myeloid leukemia (“AML”), including relapsed/refractory AML, measurable residual disease AML, and newly diagnosed TP53-mutated AML, and has since expanded to include transfusion-dependent myelodysplastic syndromes (“TD-MDS”), high-risk myelodysplastic syndromes (“HR-MDS”), and post-JAK inhibitor myelofibrosis (“MF”). Primary endpoints include safety and tolerability. Secondary endpoints include pharmacokinetics and measures of clinical response, including overall response rate (“ORR”), complete response (“CR”), composite complete response (“cCR”), and measurable residual disease (“MRD”).

About SRX Global Inc.
SRX Global is an AI-driven platform focused on generating long-term shareholder value through investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors.

About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The company’s proprietary approach to T cell engineering is designed to integrate characteristics of innate and adaptive immunity into a single therapeutic construct intended to engage multiple immune mechanisms against cancer. CERo refers to these engineered cells as Chimeric Engulfment Receptor T cells (“CER-T”).

CERo’s lead investigational product candidate, CER-1236, is being evaluated in hematologic malignancies.

Forward-Looking Statements
This communication contains forward-looking statements within the meaning of applicable securities laws. These statements include, without limitation, statements regarding the proposed transaction, including its expected timing and completion, the satisfaction of closing conditions and the go-ship process, the anticipated benefits of the proposed transaction to SRX Global and CERo, the clinical development, safety profile, pharmacokinetic and pharmacodynamic characteristics, therapeutic potential, and future evaluation of CER-1236; the progression, design, and enrollment of the CERTAIN-T trial; planned cohort expansion and dose escalation; and SRX Global’s and CERo’s development strategy and objectives. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Risks and uncertainties related to the proposed transaction include, among others, the possibility that the transaction is not completed on the anticipated timeline or at all; that the go-shop process results in a superior proposal and the termination of the purchase agreement, including the payment of termination fees; the failure to satisfy closing conditions, including those related to CERo Holdings’ preferred stock; changes in the value or liquidity of SRX common stock issued as consideration; disruption to CERo Therapeutics’ operations, personnel and business relationships; and the risks inherent in the clinical development of CER-1236, an investigational product candidate. Certain risks that could cause actual results to differ are set forth in SRX Global’s and CERo’s respective filings with the Securities and Exchange Commission, including their most recent Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in these filings are not exhaustive. Forward-looking statements are not guarantees of performance, and undue reliance should not be placed on such statements. SRX Global undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Company Contact:
SRX Global Inc.
Kent Cunningham, Chief Executive Officer

Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254

Frøya, 7 October 2026

Reference is made to Kaldvík AS’ (“Kaldvík” or the “Company”) stock exchange announcements on 6 and 15 September 2026 regarding the jellyfish event affecting the Company’s farming sites in Reyðarfjörður, and to the announcement on 1 October 2026 regarding the waiver agreement with the Company’s lenders. In the 1 October announcement, the Company noted that the jellyfish event had negatively affected its biological production and financial position.

Following continued monitoring and assessment, the Company estimates that the event has resulted in approximately 11.5 percentage points of additional mortality in the affected 2025 generation since 4 September 2026. This compares with approximately 6.5 percentage points reported on 15 September 2026.

Jellyfish presence in Reyðarfjörður has subsided. Biological conditions at the affected sites have normalized, and mortality and appetite have returned to normal levels.

Based on the Company’s current assessment, Kaldvík’s harvest guidance for 2026 remains unchanged at approximately 17,000 tonnes.

The Company will provide further information on its biological performance in connection with its Q3 2026 presentation on 13 November 2026.

About Kaldvík AS
Kaldvík is the leading salmon farmer in Iceland. Kaldvík has a well-developed and fully integrated value chain, enabling the Group to provide its customers with a sustainable premium product. Kaldvík is dual-listed on Euronext Growth Oslo and Nasdaq First North Growth Market Iceland. See www.kaldvik.is for more information about the Company.

ANCHORAGE, Alaska, Oct. 07, 2026 (GLOBE NEWSWIRE) — First National Bank Alaska (OTCQX: FBAK) today announced that Betsy Lawer, who has served as Board Chair and Chief Executive Officer/President since 2015, will transition to Executive Chair of the Board of Directors effective January 2, 2027.

First National’s Board of Directors unanimously appointed Darren Franz to become CEO/President, assuming responsibility for the bank’s operations and executive leadership team. This transition is the culmination of the bank’s long-term succession plan, reflecting its longstanding commitment to continued stability, continuity, and organizational strength.

During Lawer’s tenure, First National has grown from $3.5 billion in assets to more than $5.1 billion, earned national recognition as Forbes’ second-top-ranked bank in the nation and recognized as Alaska’s Best Place to Work for 11 consecutive years by Alaska Business readers.

“Leadership is never about one person. It’s about building an organization with the right people, shared values and the courage to look beyond today,” said Lawer. “I am deeply proud of everything our remarkable employees, executive team and Board of Directors have achieved together. I am confident the team is ready for their next step and excited about what lies ahead for First National.”

Franz brings more than three decades of Alaska banking experience and nearly seven years with First National to his role as CEO/President. During the past year, he has served as President – Lending & Administration, overseeing the Corporate Lending Division, the Combined Branch & Corporate Services Division, Treasury Management, Anchorage Branch Administration & Escrow Division, and the Central Administration Division. Franz also currently serves as a director of First National.

“Darren understands our customers, employees and culture,” Lawer said. “He has played an integral role in shaping the bank’s strategy and is well prepared to lead First National into its next phase.”

Additional leadership appointments effective January 2, 2027, include:

• Steve Patin will become Senior Executive Officer and Chief Operating Officer.
• Karl Heinz will become Senior Executive Officer and Chief Branch Administration Officer.
• Denise Brown Robinson, who remains Board Secretary, will become Executive Vice President and Senior Administrative Director.

While Lawer will step away from the day-to-day management of First National, she will continue to serve as Executive Chair of the Board, providing strategic guidance and governance leadership.

“First National has a remarkable legacy built on serving Alaskans with integrity, sound judgment and long-term perspective,” Franz said. “I’m honored to work alongside an experienced Board of Directors and exceptional leadership team. We will continue building on the momentum and culture that have made First National a trusted bank for more than 104 years.”

Alaska’s community bank since 1922, First National Bank Alaska proudly meets the financial needs of Alaskans with ATMs and 28 locations in 19 communities throughout the state, and by providing banking services to meet their needs across the nation and around the world.

For more than a century, the bank has been committed to supporting the communities it serves. In 2024, for the eighth consecutive reporting period, over a span of twenty-four years, First National received an Outstanding Community Reinvestment Act performance rating from the Office of the Comptroller of the Currency.

In 2026, Forbes named First National as one of the World’s Top Performing Banks and, for the second year in a row, one of America’s Best Banks, ranking as the second-top bank in the nation. In 2026, Alaska Business readers voted First National “Best of Alaska Business” in the Best Place to Work category for the 11^th year in a row, Best Bank/Credit Union for the sixth consecutive year, Best Customer Service for the third year in a row, Best Corporate Citizen for the fifth time and Best Wealth Management Firm. Newsweek recognized the bank as one of the nation’s 2026 Best Regional Banks and Credit Unions for the second year in a row. In 2025, American Banker recognized First National as a “Best Bank to Work For” for the eighth year in a row. The bank was also voted “Best of Alaska” in the Anchorage Daily News awards, ranking as one of the top three in the Bank/Financial category for the seventh consecutive year.

First National Bank Alaska is a Member FDIC, Equal Housing Lender, and is recognized as a Minority Depository Institution by the Office of the Comptroller of the Currency, as it is majority-owned by women.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding leadership transitions, future roles and responsibilities, strategic direction, and the First National Bank Alaska’s future performance. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results or events to differ materially. Forward-looking statements speak only as of the date made, and First National Bank Alaska undertakes no obligation to update them except as required by law.

Contact Corporate Communications
907-777-3409

Agreement includes options to purchase 1,000,000 shares at $1.15 per share and performance-based award tied to earnings, with thresholds above $0.05 EBITDA per share for 2027

NETANYA, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) — Tessera Defense and Homeland Security Inc. (“Tessera” or the “Company”) (NYSE American: HLSQ) today announced that the Company and its wholly owned Israeli subsidiary have entered into an employment agreement with Michael Oster, the Company’s Chief Executive Officer. Mr. Oster was appointed CEO of the Company as of March 4, 2026.

Under the agreement, Mr. Oster is entitled to, subject to the approvals described below, an option to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $1.15 per share, as well as 1,000,000 restricted stock units vesting over three years and 400,000 fully vested shares of common stock in recognition of his service since March 2026.

A portion of Mr. Oster’s equity compensation will be tied to the Company’s EBITDA per share. For FY 2027, Mr. Oster will be entitled to 200,000 shares if EBITDA per share exceeds $0.05, plus an additional 100,000 shares for each full cent ($0.01) above that level, up to a maximum of 500,000 shares.

For FY 2028, the same structure applies above a threshold of $0.10 per share, also up to a maximum of 500,000 shares. For this purpose, EBITDA means earnings before net financing expenses, income taxes, depreciation and amortization, and EBITDA per share means EBITDA divided by the weighted average number of shares outstanding used to calculate basic earnings per share, in each case based on the Company’s audited consolidated financial statements for the relevant year, prepared in accordance with U.S. GAAP.

EBITDA and EBITDA per share are not measures calculated in accordance with U.S. GAAP. All of the equity awards described above, including the fully vested shares, are subject to required corporate approvals, including stockholder approval of an increase in the number of shares available under the Company’s equity incentive plan, as well as NYSE American approval of the listing of the underlying shares.

In addition, Mr. Oster is the acting Chairman of the Board of Directors of the Company’s subsidiaries.

To date, the Company has also raised more than $6 million in net proceeds through its at-the-market offering program at an average net price of approximately $1.15 per share, as adjusted for the Company’s one-for-ten reverse stock split. In addition, an existing financing source of the Company recently agreed to increase the Company’s available resources by $5 million through a line of credit to support the Company’s business.

“Michael has led Tessera through a fundamental transformation,” said Reuven Yeganeh, a Director. “He has overseen the company’s move from biotechnology into defense and homeland security technology, completed the acquisitions of Zorronet and DFSL, and laid the foundation for additional growth. This agreement reflects the Board’s confidence in his leadership and aligns a meaningful portion of his compensation with stockholder interests through EBITDA-per-share performance.”

“I am grateful to the Board for its confidence, and I believe deeply in Tessera, our people and our technology,” said Michael Oster, CEO of Tessera. “Linking a significant part of my compensation to EBITDA per share reflects my conviction in our path to profitable growth. My interests are aligned with those of our stockholders, and I am fully committed to building long-term value for them.”

Further details of Mr. Oster’s compensation arrangement are included in a Current Report on Form 8-K filed today with the Securities and Exchange Commission (the “SEC”).

Additional Information and Where to Find It

The equity awards to Mr. Oster are conditioned on stockholder approval of the amendment to the 2026 Equity Incentive Plan at the Company’s Special Meeting of Stockholders to be held on October 20, 2026 (the “Special Meeting”). The Company has filed a definitive proxy statement for the Special Meeting with the SEC and will file a supplement to it describing these awards. STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND THE SUPPLEMENT, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION. These documents are available free of charge at www.sec.gov and at https://www.cstproxy.com/tessera/2026. The Company and its directors and executive officers, including Mr. Oster, may be deemed participants in the solicitation of proxies for the Special Meeting. Information about their interests is set forth in the definitive proxy statement and will be set forth in the supplement.

About Tessera Defense and Homeland Security Inc. (Formerly BiomX Inc.)

Tessera Defense and Homeland Security Inc. (NYSE American: HLSQ) is a physical security technology company providing integrated, bespoke security solutions that connect detection, intelligence and response across complex security environments. The Tessera platform integrates cameras, sensors, detection technologies, AI and other security infrastructure to identify threats, understand events and coordinate response in real time. Tessera provides the technology, hardware and implementation expertise needed to tailor security solutions to the specific requirements of each site, helping customers deploy and optimize integrated security systems across critical infrastructure, energy, digital infrastructure and homeland security applications.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words such as “expects,” “intends,” “plans,” “believes,” “targets,” “will,” “may,” “anticipates,” “estimates,” “potential,” “projects,” and similar expressions. These forward-looking statements include, among other things, statements regarding the Company’s expectations regarding future growth and profitability; the potential achievement of the EBITDA-per-share performance thresholds applicable to Mr. Oster’s equity compensation for fiscal years 2027 and 2028; the potential issuance of shares pursuant to such performance-based awards; the availability and use of funds under the Company’s at-the-market offering program and line of credit; and the receipt of required corporate approvals, including stockholder approval of an increase in the Company’s equity incentive plan.

These statements are based on the Company’s current expectations, assumptions and strategic plans and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied. There can be no assurance that the Company will achieve any particular level of EBITDA or EBITDA per share, that any of the performance-based equity awards will be earned or issued, or that the required corporate or stockholder approvals will be obtained.

These risks and uncertainties include, among others: the risk that the Company may not achieve the EBITDA-per-share thresholds applicable to the performance-based equity awards; the risk that the Company’s revenue, expenses, profitability, number of shares outstanding or other financial results may differ materially from current expectations; the Company’s ability to successfully execute its business strategy and achieve profitable growth; the Company’s ability to integrate and commercialize its technologies and acquired businesses; changes in customer demand, competitive conditions, government or private-sector spending, procurement processes, regulatory requirements, geopolitical conditions, supply-chain conditions or other market factors; the Company’s ability to raise additional capital and execute its business and strategic initiatives; the Company’s going concern qualification; the risk that required corporate or stockholder approvals relating to the equity awards or the Company’s equity incentive plan may not be obtained; the risk that the Company may not regain compliance with the NYSE American continued listing standards within the plan period or at all; the risk that the Company may not make progress consistent with its compliance plan; the possibility that the Company’s common stock may be suspended from trading or delisted from the NYSE American; and the other risks described in the Company’s filings with the SEC, including under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 19, 2026, as supplemented by the Form 10-K/A filed with the SEC on April 30, 2026, the Company’s Current Report on Form 8-K filed with the SEC on May 5, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 19, 2026, as well as the Company’s other filings with the SEC.

The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact
Yair Ohayon
Yairo@thlsq.ai

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 7 OCTOBER 2026 AT 21.30 P.M. EEST, MAJOR SHAREHOLDER ANNOUNCEMENT

Notification under Chapter 9, Section 10 of the Securities Market Act: Holdings of S-Bank Plc in Oma Savings Bank Plc has exceeded 90 percent

S-Bank Plc has completed its tender offer for all issued and outstanding shares in Oma Savings Bank Plc  (OmaSp). Settlement of the shares tendered under the tender offer took place on 7 October 2026.

On 7 October 2026, Oma Savings Bank Plc received a notification under Chapter 9, Section 5 of the Securities Market Act (SMA) from S-Bank Plc (business ID 2557308-3), according to which S-Bank Plc’s holding and voting rights in OmaSp has exceeded 90 percent on 7 October 2026.

According to the announcement, S-Bank Plc owns 32 155 420 OmaSp shares, corresponding to 96,40 percent of OmaSp’s shares and votes.

OmaSp has one class of shares in which each share has one vote. The total number of shares is 33,356,729.

The holding of S-Bank Plc according to the announcement:

	% of shares and voting rights (A)	% of shares and voting rights through financial instruments (B)	Total of both in % (A+B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	96,40%	0	96,40%	33 356 729
Positions of previous notification (if threshold crossed)	N/A	N/A	N/A	N/A

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Shares and voting rights:

Class/type of shares	Number of shares and voting rights		% of shares and voting rights
ISIN code	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
FI4000306733	32 155 420	0	96,40	0
A total	32 155 420		96,40

Oma Savings Bank Plc

Additional information:

Karri Alameri, CEO, tel. +358 20 758 3040, karri.alameri@omasp.fi

Distribution:

Nasdaq Helsinki Ltd
Major media
www.omasp.fi

Oma Savings Bank is a well-capitalised and profitable Finnish bank that serves over 200,000 personal and corporate customers through 48 branches across Finland and digital channels with approximately 600 experts. Oma Savings Bank’s key objective is a first-class customer experience through personal service and easy accessibility in both digital and traditional channels. Oma Savings Bank focuses primarily on retail banking and offers its customers a diverse range of banking services both through its own balance sheet and by intermediating products of its cooperation partners, such as credit, investment and loan protection products. Oma Savings Bank also engages in mortgage banking operations. The Shares of Oma Savings Bank are listed on the regulated market maintained by Nasdaq Helsinki. Oma Savings Bank is a part of S-Bank Group.

Company Reports Significant Improvement in Gross Profit, Net Loss and Operating Cash Used for the First Half of 2026; Continues to Expand Healthcare Customer Base and AI-Enabled Data Management Platform

MIDDLETON, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) — SCWorx Corp. (Nasdaq: WORX) (“SCWorx” or the “Company”), a provider of healthcare supply chain data management and analytics solutions,  following the resumption of trading of its common stock today on The Nasdaq Capital Market, highlighted the Company’s improved operating performance, expanding healthcare customer relationships and continued investment in its proprietary healthcare data and technology platform.

The resumption of Nasdaq trading represents an important milestone for SCWorx and provides the Company with a platform to pursue its next phase of growth following significant improvements in gross profitability and cash utilization during the first half of 2026. As previously announced, on October 2, 2026 the Nasdaq Hearings Panel granted the Company’s request for reconsideration of its September 17, 2026 delisting decision, determined that the Company had regained compliance with Nasdaq’s continued listing requirements and approved the Company’s continued listing on The Nasdaq Capital Market, subject to conditions that include a one-year Panel Monitor. The Panel’s decision and its conditions are described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on October 5, 2026.

Building a Stronger and More Scalable SCWorx

“The resumption of Nasdaq trading is an important milestone for SCWorx and our shareholders, but our focus remains firmly on the underlying business,” said Tim Hannibal, President and Chief Executive Officer of SCWorx. “Over the past year, we have significantly improved the economics of the Company while continuing to invest in our technology, healthcare data assets and customer relationships. We believe we are building a more efficient, scalable and strategically valuable healthcare technology company.”

The following financial information is derived from the Company’s unaudited condensed consolidated financial statements included in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 14, 2026. For the second quarter of 2026, SCWorx generated revenue of approximately $706,000, compared with approximately $683,000 in the second quarter of 2025. Gross profit increased approximately 83% to approximately $330,000, compared with approximately $180,000 in the prior-year period.

For the first six months of 2026, gross profit increased approximately 122% to approximately $705,000, compared with approximately $317,000 in the prior-year period, despite comparatively modest revenue growth (approximately $1.45 million compared with approximately $1.40 million).

The Company’s net loss for the second quarter declined to approximately $121,000, compared with a net loss of approximately $1.9 million in the second quarter of 2025. For the first six months of 2026, the Company’s net loss was approximately $295,000, compared with approximately $2.4 million during the comparable period in 2025. The decrease in net loss was attributable to the increase in gross profit and to the absence in 2026 of approximately $1.7 million of interest expense and amortization of debt discount recorded in the first six months of 2025 in connection with convertible notes that are no longer outstanding; operating expenses were essentially unchanged.

Cash used in operating activities also declined substantially, to approximately $258,000 during the first six months of 2026, compared with approximately $1.1 million during the comparable period in 2025. The Company had cash of approximately $1.3 million at June 30, 2026 and, in September 2026, raised gross proceeds of $938,000 in a private placement of common stock and warrants.

Management believes the improvement in gross profit demonstrates the potential operating leverage of the SCWorx business model as the Company seeks to grow revenue using a more efficient technology and delivery infrastructure.

A Differentiated Healthcare Data Platform

SCWorx is focused on solving one of the most persistent challenges facing healthcare providers: the lack of clean, standardized, complete and actionable supply chain data.

Healthcare organizations frequently operate with fragmented item masters, inconsistent product descriptions, incomplete product attributes, multiple classification systems and disconnected supplier information. These data-quality challenges can affect procurement, inventory management, contract compliance, analytics, ERP implementations and financial performance.

SCWorx has spent more than a decade developing healthcare-specific product data, classification methodologies, attribute structures and data-management capabilities designed to address these challenges.

The Company’s competitive differentiation is based on the combination of its curated healthcare product data assets, proprietary classification and attribute methodologies, healthcare-specific domain expertise, technology-enabled workflows and human quality-assurance processes.

During 2026, SCWorx has continued to expand these capabilities through its AI-enabled Data Management Model, which combines commercially available large language models with SCWorx’s healthcare data assets, attribute catalog, classification methodologies and human quality assurance.

SCWorx believes AI-enabled automation can materially improve the economics and scalability of its data-management operations by accelerating data-processing workflows, increasing automation and reducing the resources required to cleanse, normalize, classify and enrich healthcare supply chain data.

“We believe the strategic value of SCWorx extends beyond an individual software application,” Hannibal continued. “Over more than a decade, we have developed healthcare-specific data, classification methodologies, attribute structures and institutional knowledge that are embedded in our platform and workflows. Combining these assets with AI-enabled automation creates an opportunity to process healthcare data faster and more efficiently while continuing to maintain the domain expertise and quality controls our customers require.”

Expanding Healthcare Customer Relationships

Customer expansion and recurring revenue remain core priorities for SCWorx.

During 2026, the Company has announced new agreements and customer wins involving major healthcare organizations, including a new not-for-profit teaching hospital utilizing SCWorx data-management capabilities in support of a Workday implementation and a new two-year agreement with one of Massachusetts’ largest integrated delivery networks.

The Company has also continued to develop relationships with strategic healthcare and technology partners.

SCWorx believes these relationships demonstrate the broader role that high-quality supply chain data can play within modern healthcare technology environments.

The Company’s opportunity extends beyond individual data-cleansing projects. Once SCWorx data and technology are incorporated into a healthcare organization’s operating environment, the Company believes opportunities may exist to provide ongoing data governance, enrichment, classification, interoperability and analytics services.

Increasing the percentage of revenue generated from recurring and multi-year customer relationships remains an important component of SCWorx’s long-term strategy.

Priorities for the Next Stage of Growth

SCWorx’s objective is to build a profitable and scalable healthcare data-management company with recurring revenue, proprietary healthcare data capabilities and technology-enabled operating leverage at its core.

The Company is concentrating its resources on four primary priorities:

1. Expanding its healthcare customer base through direct sales and strategic channel relationships;
2. Increasing recurring and multi-year revenue from new and existing customers;
3. Improving gross margins and operating leverage through automation, AI-enabled workflows and continued optimization of the Company’s technology infrastructure; and
4. Expanding the strategic value and application of SCWorx’s healthcare data, classification methodologies and technology across supply chain, ERP, procurement, analytics and interoperability environments.

Management believes these initiatives have the potential to create a business that is substantially more scalable and strategically valuable than the Company’s historical operating model.

Nasdaq Platform and Capital Strategy

SCWorx believes its Nasdaq listing provides an important platform to increase the Company’s visibility among investors, healthcare customers, strategic partners and potential sources of capital.

The Company’s long-term success, however, will ultimately depend upon operating performance and execution.

SCWorx intends to remain focused on growing revenue, increasing recurring revenue, improving profitability, strengthening its balance sheet and expanding the strategic value of its healthcare data and technology platform.

Management believes the combination of an improved gross margin profile, established healthcare customer relationships, healthcare-specific data assets, domain expertise and AI-enabled technology provides SCWorx with a stronger foundation from which to pursue these objectives.

Strategic Outlook

SCWorx remains a small company operating in a highly competitive healthcare technology market. The Company must continue to improve revenue growth, manage its capital resources carefully, and successfully execute its commercial strategy. The Company must also maintain compliance with Nasdaq’s continued listing requirements during the one-year Panel Monitor period, during which any deficiency would result in a Staff Delisting Determination without the benefit of a compliance plan or cure period.

At the same time, management believes SCWorx is operating from a significantly stronger foundation than it was a year ago.

The Company has improved gross profitability, substantially reduced its net loss, reduced operating cash utilization, continued to win and retain healthcare customers and invested in technology and AI-enabled capabilities designed to increase the scalability of its operations.

“Our goal now is execution,” Hannibal said. “We intend to convert the operational improvements we have made into sustainable revenue growth, increased recurring revenue, positive cash flow and long-term shareholder value. We believe SCWorx has valuable healthcare data assets, technology and domain expertise, and our responsibility is to translate those assets into a larger, stronger and more valuable company.”

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include statements regarding, among other things, the Company’s expectations and objectives concerning revenue growth, recurring revenue, gross margins, operating leverage, profitability, positive cash flow, customer expansion, strategic relationships, capital resources, technology development, AI-enabled data management, scalability, market opportunities and shareholder value.

Forward-looking statements are based on management’s current expectations, estimates and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the Company’s ability to grow revenue and recurring revenue, retain and expand customer relationships, successfully develop and deploy new technology, realize anticipated efficiencies from AI-enabled automation, compete successfully in the healthcare technology market. manage its capital resources, raise additional capital on acceptable terms, if at all, the dilutive effect of any equity financing, maintain compliance with applicable Nasdaq continued-listing requirements, including during the one-year Panel Monitor period, the possibility that the Nasdaq Listing and Hearing Review Council calls the Nasdaq Hearings Panel’s October 2, 2026 decision for review, and the possibility that the investors in the Company’s September 2026 private placement exercise their contractual termination rights, The results for the periods ended June 30, 2026 described in this press release are not necessarily indicative of results for any future period.

Readers are encouraged to review the risk factors and other disclosures contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. SCWorx undertakes no obligation to publicly update or revise any forward-looking statements except as required by applicable law.

About SCWorx Corp.

SCWorx Corp. is a healthcare technology company providing data management, normalization, enrichment, interoperability and analytics solutions focused on healthcare supply chain and related operational data.

The Company’s platform combines curated healthcare product data assets, proprietary classification and attribute methodologies, healthcare-specific domain expertise and technology-enabled workflows designed to help healthcare organizations improve the quality, consistency and usability of their data.

SCWorx solutions support healthcare supply chain, procurement, ERP, analytics and financial initiatives and are designed to help healthcare organizations transform fragmented product information into standardized and actionable data.

For more information, visit SCWorx’s corporate website.

Investor Contact

SCWorx Investor Relations
ir@scworx.com

Change in the composition of the Board of Directors
Co-option of two independent directors 

Paris, October 7, 2026

The Board of Directors of Christian Dior announces that it has today co-opted, effective immediately, Mr. Tony Estanguet and Mr. Xavier Musca as independent directors within the meaning of the Afep-Medef Code, to replace two resigning directors, Mr. Nicolas Bazire and Ms. Maria Luisa Loro Piana.

Mr. Tony Estanguet has been appointed as a Member of the Performance Audit Committee, and Mr. Xavier Musca has been appointed as a Member of both the Performance Audit Committee and the Governance and Compensation Committee.

This change is part of the project to simplify its corporate structures being contemplated by the Arnault family group and announced on September 23, 2026, which would then trigger the filing of a mandatory tender offer (offre publique de retrait) on Christian Dior shares, without implementing a squeeze-out.

* * *

Biographies

Tony Estanguet is a French canoe-kayak slalom (C1) champion and sports executive. He is the first French athlete to win three Olympic gold medals at three different Games (2000, 2004 and 2012). He chaired the Organizing Committee of the Paris 2024 Olympic and Paralympic Games.

Xavier Musca is a French senior official, economist, and business executive. After a career in the senior civil service (notably as Director of the French Treasury and Secretary General of the President’s Office), he moved into private-sector banking, specifically within the Crédit Agricole group, before becoming Chairman of the Supervisory Board of Tikehau Capital.

Attachment

• Christian Dior SE – Change in the composition of the Board of Directors

SINGAPORE, Oct. 07, 2026 (GLOBE NEWSWIRE) — SMJ International Holdings Inc. (NYSE American: SMJF) (the “Company”) today announced that it has received a public warning letter, dated October 6, 2026 (the “Warning Letter”), issued by NYSE Regulation on behalf of NYSE American LLC (the “Exchange”), regarding the Company’s disclosure of material news in a manner that failed to comply with Section 401(a) of the NYSE American Company Guide (the “Company Guide”).

Section 401(a) of the Company Guide requires a listed company to make immediate public disclosure of all material information concerning its affairs and, when such disclosure is to be made between 7:00 A.M. and 4:00 P.M. Eastern Time, to notify the Exchange at least ten minutes prior to the announcement.

According to the Warning Letter, at approximately 4:33 P.M. Eastern Time on October 1, 2026, the Company filed a Report on Form 6-K with the U.S. Securities and Exchange Commission (the “SEC”) disclosing, among other things, that on September 29, 2026, Ms. Lee Lay Choo tendered her resignation as an executive director of the Board of Directors of the Company and Ms. Low Yeen Mei Sherina resigned as Chief Financial Officer of the Company, effective immediately. The Warning Letter states that, when the Company disclosed this material information on October 1, 2026, the Company failed to comply with Section 401(a) of the Company Guide because the Company did not make immediate public disclosure of the September 29, 2026 material information.

The Warning Letter also notes that NYSE Regulation staff previously reminded the Company of its obligations under Section 401(a) of the Company Guide on February 17, 2026 and August 27, 2026, in connection with other NYSE Regulation staff inquiries into trading activity in the Company’s shares.

The Warning Letter further states that, as a result of the foregoing, the Exchange has determined that the Company violated Section 401(a) of the Company Guide and that, in accordance with Section 1009(a)(i) of the Company Guide, NYSE Regulation issued the Company the Warning Letter.

This announcement is being made in accordance with Section 401(j) of the Company Guide, which requires a separate public disclosure of the Warning Letter by the Company. The Company takes its disclosure obligations seriously and is reviewing and enhancing its procedures for the timely dissemination of material information to ensure future compliance with the Company Guide.

About SMJ International Holdings Inc.

SMJ International Holdings Inc. and its subsidiaries (“SMJ Group”) are Singapore-based premier flooring specialists that have a well-established reputation and track records with the commercial and institutional sectors in Asia. It specializes in the sale and distribution of a wide range of premier flooring products such as carpet tiles, broadloom carpets and vinyl tiles under its proprietary brand known as “SMJ” in Singapore and over 20 countries mainly in Asia. To meet the increasing demand for green and eco-friendly materials in Asia, SMJ Group also supplies flooring products that have been certified as environmentally friendly to support government initiatives in promoting sustainable building practices in Asia. For more information, visit https://smjf.com.sg/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “we believe,” “we intend,” “may,” “should,” “will,” “could” and similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequently occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:

Investor Relations
SMJ International Holdings Inc.
+65 6261-1212
media@smjf.com.sg